Disclaimer:

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.10576 – BAIN CAPITAL / HELLMAN & FRIEDMAN / ATHENAHEALTH GROUP

SECTION 1.2

Description of the concentration

The proposed concentration, notified to the European Commission on 10 January 2022, concerns the acquisition, by way of a purchase of shares, of joint control of athenahealth Group Inc. ("athenahealth" or "Target") by funds managed or advised by Bain Capital Investors L.L.C. ("Bain Capital") and funds advised by Hellman & Friedman LLC ("Hellman & Friedman") (the "Proposed Transaction").

As a result of the Proposed Transaction, funds managed or advised by each of Bain Capital and Hellman & Friedman will acquire indirect, joint control of athenahealth within the meaning of Article 3(1)(b) and Article 3(4) of the EU Merger Regulation.

Bain Capital, incorporated in the United States, is a private equity investment firm that invests in companies across a number of industries, including information technology, healthcare, retail and consumer products, communications, financial services and industrial/manufacturing.

Hellman & Friedman, incorporated in the United States, is a private equity firm focused on market-leading firms with growth potential, and has investments in a variety of sectors worldwide. It has offices in San Francisco, New York and London.

athenahealth, headquartered in Massachusetts, USA, is a US-based cloud-based provider of medical record, revenue cycle, patient engagement, care coordination, and population health services, as well as point-of-care mobile applications. athenahealth is not active within the EEA.